Original Article

You have full text access to this OnlineOpen article

Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage

  1. William N Addison1,
  2. David L Masica2,
  3. Jeffrey J Gray2,3,
  4. Marc D McKee1,4,*

Article first published online: 14 DEC 2009

DOI: 10.1359/jbmr.090832

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 4, pages 695–705, April 2010

Additional Information

How to Cite

Addison, W. N., Masica, D. L., Gray, J. J. and McKee, M. D. (2010), Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage. J Bone Miner Res, 25: 695–705. doi: 10.1359/jbmr.090832

Author Information

  1. 1

    Faculty of Dentistry, McGill University, Montreal, Quebec, Canada

  2. 2

    Program in Molecular Biophysics, The Johns Hopkins University, Baltimore, MD, USA

  3. 3

    Department of Chemical and Biomolecular Engineering, The John Hopkins University, Baltimore, MD, USA

  4. 4

    Department of Anatomy and Cell Biology, McGill University, Montreal, Quebec, Canada

*Faculty of Dentistry, McGill University, 3640 University Street, Montreal, Quebec, Canada H3A 2B2.

Publication History

  1. Issue published online: 9 APR 2010
  2. Article first published online: 14 DEC 2009
  3. Accepted manuscript online: 27 JAN 2010 12:00AM EST
  4. Manuscript Accepted: 27 AUG 2009
  5. Manuscript Revised: 23 JUN 2009
  6. Manuscript Received: 16 JAN 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (400K)

References

  • 1
    Boskey AL. Biomineralization: an overview. Connect Tissue Res. 2003; 44: 5–9.
  • 2
    Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med. 2000; 11: 279–303.
  • 3
    Giachelli CM. Inducers and inhibitors of biomineralization: lessons from pathological calcification. Orthod Craniofac Res. 2005; 8: 229–231.
    Direct Link:
  • 4
    Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993; 7: 1475–1482.
  • 5
    Christensen B, Nielsen MS, Haselmann KF, Petersen TE, Sorensen ES. Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J. 2005; 390: 285–292.
  • 6
    Keykhosravani M, Doherty-Kirby A, Zhang C, Brewer D, Goldberg HA, Hunter GK, Lajoie G. Comprehensive identification of post-translational modifications of rat bone osteopontin by mass spectrometry. Biochemistry. 2005; 44(18): 6990–7003.
  • 7
    Christensen B, Kazanecki CC, Petersen TE, Rittling SR, Denhardt DT, Sorensen ES. Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. J Biol Chem. 2007; 282(27): 19463–72.
  • 8
    Gericke A, Qin C, Spevak L, Fujimoto Y, Butler WT, Sorensen ES, Boskey AL. Importance of phosphorylation for osteopontin regulation of biomineralization. Calcif Tissue Int. 2005; 77(1): 45–54.
  • 9
    Kazanecki CC, Uzwiak DJ, Denhardt DT. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem. 2007; 102(4): 912–24.
    Direct Link:
  • 10
    Agnihotri R, Crawford HC, Haro H, Matrisian LM, Havrda MC, Liaw L. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J. Biol. Chem. 2001; 276(30): 28261–28267.
  • 11
    Dean RA, Overall CM. Proteomics Discovery of Metalloproteinase Substrates in the Cellular Context by iTRAQTM Labeling Reveals a Diverse MMP-2 Substrate Degradome. Mol Cell Proteomics. 2007; 6(4): 611–623.
  • 12
    Rowe PSN, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Navvab S, Chen D, Drezner MK, Quarles LD, Mundy GR. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone. 2004; 34(2): 303–319.
  • 13
    Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, Oudet CL. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics. 2000; 67(1): 54–68.
  • 14
    Addison WN, Nakano Y, Loisel T, Crine P, McKee MD. MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM. J Bone Miner Res. 2008; 23(10): 1638–49.
    Direct Link:
  • 15
    Fisher LW, Fedarko NS. Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res. 2003; 44 (Suppl 1): 33–40.
  • 16
    Liu S, Rowe PS, Vierthaler L, Zhou J, Quarles LD. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol. 2007; 192(1): 261–7.
  • 17
    Rowe PS, Matsumoto N, Jo OD, Shih RN, Oconnor J, Roudier MP, Bain S, Liu S, Harrison J, Yanagawa N. Correction of the mineralization defect in Hyp mice treated with protease inhibitors CA074 and pepstatin. Bone. 2006; 39(4): 773–86.
  • 18
    Bresler D, Bruder J, Mohnike K, Fraser WD, Rowe PS. Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. J Endocrinol. 2004; 183(3): R1–9.
  • 19
    Bai X, Miao D, Panda D, Grady S, McKee MD, Goltzman D, Karaplis AC. Partial rescue of the Hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) expression. Mol Endocrinol. 2002; 16(12): 2913–25.
  • 20
    Martin A, David V, Laurence JS, Schwarz PM, Lafer EM, Hedge A-M, Rowe PSN. Degradation of MEPE, DMP1, and Release of SIBLING ASARM-Peptides (Minhibins): ASARM-Peptide(s) Are Directly Responsible for Defective Mineralization in HYP. Endocrinology. 2008; 149(4): 1757–1772.
  • 21
    Boileau G, Tenenhouse HS, Desgroseillers L, Crine P. Characterization of PHEX endopeptidase catalytic activity: identification of parathyroid-hormone-related peptide 107–139 as a substrate and osteocalcin, PPi and phosphate as inhibitors. Biochem J. 2001; 355(Pt 3): 707–13.
  • 22
    Wang D, Christensen K, Chawla K, Xiao G, Krebsbach PH, Franceschi RT. Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J Bone Miner Res. 1999; 14(6): 893–903.
    Direct Link:
  • 23
    Sudo H, Kodama HA, Amagai Y, Yamamoto S, Kasai S. In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J Cell Biol. 1983; 96(1): 191–8.
  • 24
    Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival: Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. Journal of Immunological Methods. 1986; 89(2): 271–277.
  • 25
    Tullberg-Reinert H, Jundt G. In situ measurement of collagen synthesis by human bone cells with a sirius red-based colorimetric microassay: effects of transforming growth factor β2 and ascorbic acid 2-phosphate. Histochem Cell Biol. 1999; 112(4): 271–6.
  • 26
    Masica DL, Gray JJ. Solution- and adsorbed-state structural ensembles predicted for the statherin-hydroxyapatite system. Submitted. 2008.
  • 27
    Makrodimitris K, Masica DL, Kim ET, Gray JJ. Structure Prediction of Protein-Solid Surface Interactions Reveals a Molecular Recognition Motif of Statherin for Hydroxyapatite. J Am Chem Soc. 2007; 129(44): 13713–13722.
  • 28
    Pampena DA, Robertson KA, Litvinova O, Lajoie G, Goldberg HA, Hunter GK. Inhibition of hydroxyapatite formation by osteopontin phosphopeptides. Biochem J. 2004; 378(Pt 3): 1083–7.
  • 29
    Hunter GK, Kyle CL, Goldberg HA. Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. Biochem J. 1994; 300(Pt 3): 723–8.
  • 30
    Hoyer JR, Asplin JR, Otvos L. Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. Kidney Int. 2001; 60(1): 77–82.
  • 31
    Grohe B, O'Young J, Ionescu DA, Lajoie G, Rogers KA, Karttunen M, Goldberg HA, Hunter GK. Control of calcium oxalate crystal growth by face-specific adsorption of an osteopontin phosphopeptide. J Am Chem Soc. 2007; 129(48): 14946–51.
  • 32
    Wang L, Guan X, Tang R, Hoyer JR, Wierzbicki A, De Yoreo JJ, Nancollas GH. Phosphorylation of Osteopontin Is Required for Inhibition of Calcium Oxalate Crystallization. The Journal of Physical Chemistry B. 2008; 112(30): 9151–9157.
  • 33
    Boskey AL, Spevak L, Paschalis E, Doty SB, McKee MD. Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone. Calcif Tissue Int. 2002; 71(2): 145–54.
  • 34
    Gowen LC, Petersen DN, Mansolf AL, Qi H, Stock JL, Tkalcevic GT, Simmons HA, Crawford DT, Chidsey-Frink KL, Ke HZ, McNeish JD, Brown TA. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem. 2003; 278(3): 1998–2007.
  • 35
    Hunter GK, Hauschka PV, Poole AR, Rosenberg LC, Goldberg HA. Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Biochem J. 1996; 317(Pt 1): 59–64.
  • 36
    Goldberg HA, Hunter GK. The inhibitory activity of osteopontin on hydroxyapatite formation in vitro. Ann NY Acad Sci. 1995; 760: 305–8.
    Direct Link:
  • 37
    Boskey AL, Maresca M, Ullrich W, Doty SB, Butler WT, Prince CW. Osteopontin-hydroxyapatite interactions in vitro: inhibition of hydroxyapatite formation and growth in a gelatin-gel. Bone Miner. 1993; 22(2): 147–59.
  • 38
    Sorensen ES, Hojrup P, Petersen TE. Posttranslational modifications of bovine osteopontin: identification of twenty-eight phosphorylation and three O-glycosylation sites. Protein Sci. 1995; 4(10): 2040–9.
    Direct Link:
  • 39
    Lasa M, Chang PL, Prince CW, Pinna LA. Phosphorylation of osteopontin by Golgi apparatus casein kinase. Biochem Biophys Res Commun. 1997; 240(3): 602–5.
  • 40
    Lasa-Benito M, Marin O, Meggio F, Pinna LA. Golgi apparatus mammary gland casein kinase: monitoring by a specific peptide substrate and definition of specificity determinants. FEBS Lett. 1996; 382(1–2): 149–152.
  • 41
    Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2? FASEB J. 2003; 17(3): 349–368.
  • 42
    Addison WN, Azari F, Sorensen ES, Kaartinen MT, McKee MD. Pyrophosphate Inhibits Mineralization of Osteoblast Cultures by Binding to Mineral, Up-regulating Osteopontin, and Inhibiting Alkaline Phosphatase Activity. J. Biol. Chem. 2007; 282(21): 15872–15883.
  • 43
    Jono S, Peinado C, Giachelli CM. Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem. 2000; 275(26): 20197–203.
  • 44
    Hunter GK, Grohe B, Jeffrey S, O'Young J, Sorensen ES, Goldberg HA. Role of Phosphate Groups in Inhibition of Calcium Oxalate Crystal Growth by Osteopontin. Cells Tissues Organs. 2008.
  • 45
    Kasugai S, Zhang Q, Overall CM, Wrana JL, Butler WT, Sodek J. Differential regulation of the 55 and 44 kDa forms of secreted phosphoprotein 1 (SPP-1, osteopontin) in normal and transformed rat bone cells by osteotropic hormones, growth factors and a tumor promoter. Bone Miner. 1991; 13(3): 235–50.
  • 46
    Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS. Flexible Structures of SIBLING Proteins, Bone Sialoprotein, and Osteopontin. Biochemical and Biophysical Research Communications. 2001; 280(2): 460–465.
  • 47
    Goobes G, Goobes R, Schueler-Furman O, Baker D, Stayton PS, Drobny GP. Folding of the C-terminal bacterial binding domain in statherin upon adsorption onto hydroxyapatite crystals. Proc Natl Acad Sci USA. 2006; 103(44): 16083–16088.
  • 48
    Guo R, Rowe PSN, Liu S, Simpson LG, Xiao Z-S, Darryl Quarles L. Inhibition of MEPE cleavage by PHEX. Biochemical and Biophysical Research Communications. 2002; 297(1): 38.
  • 49
    Rowe PSN, Garrett IR, Schwarz PM, Carnes DL, Lafer EM, Mundy GR, Gutierrez GE. Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Bone. 2005; 36(1): 33–46.
  • 50
    Oefner C, D'Arcy A, Hennig M, Winkler FK, Dale GE. Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon. J Mol Biol. 2000; 296(2): 341–9.
View Full Article with Supporting Information (HTML) Get PDF (400K)